Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Dec 29;14(1):51.
doi: 10.3390/jpm14010051.

Perspectives on Post-COVID-19 Pulmonary Fibrosis Treatment

Elena Cojocaru  1 , Tudor Cojocaru  2 , Giulia Mihaela Pînzariu  2 , Ioana Vasiliu  1 , Ioana Armașu  2 , Cristian Cojocaru  3
Affiliations
Review

Perspectives on Post-COVID-19 Pulmonary Fibrosis Treatment

Elena Cojocaru et al. J Pers Med. .

Abstract

Pulmonary fibrosis, a critical outcome of chronic inflammatory diseases, has gained prominence in the context of post-coronavirus (post-COVID-19) complications. This review delves into the multifaceted landscape of post-COVID-19 pulmonary fibrosis, elucidating the intricate molecular mechanisms underlying its pathogenesis and highlighting promising therapeutic avenues. Examining the aftermath of severe acute respiratory syndrome-2 (SARS-CoV-2) infection, the review reveals key signaling pathways implicated in the fibrotic cascade. Drawing parallels with previous coronavirus outbreaks enhances our understanding of the distinctive features of post-COVID-19 fibrosis. Antifibrotic drugs, like pirfenidone and nintedanib, take center stage; their mechanisms of action and potential applications in post-COVID-19 cases are thoroughly explored. Beyond the established treatments, this review investigates emerging therapeutic modalities, including anti-interleukin agents, immunosuppressants, and experimental compounds, like buloxybutide, saracatinib, sirolimus, and resveratrol. Emphasizing the critical importance of early intervention, this review highlights the dynamic nature of post-COVID-19 pulmonary fibrosis research. In conclusion, the synthesis of current knowledge offers a foundation for advancing our approaches to the prevention and treatment of these consequential sequelae of COVID-19.

Keywords: antifibrotic; fibrosis; nintedanib; pirfenidone; post-COVID-19; pulmonary; treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 2
Figure 2
The mechanisms of action of pirfenidone.
Figure 1
Figure 1
Signal pathways linked to post-COVID-19 pulmonary fibrosis pathophysiology. Legend: YAP—yes-associated protein 1; TAZ—transcriptional coactivator with PDZ-binding motif; TLR—toll-like receptor; TGF-β—transforming growth factor-beta; MAPK—mitogen-activated protein kinase; WNT—wingless/Int; PDGF—platelet-derived growth factor; VEGF—vascular endothelial growth factor; NF-κB—nuclear factor-kappa B; ET-1—endothelin-1; HIF—hypoxia-inducible factor.
See this image and copyright information in PMC

References

    1. Cui J., Li F., Shi Z.L. Origin and evolution of pathogenic coronaviruses. Nat. Rev. Microbiol. 2019;17:181–192. doi: 10.1038/s41579-018-0118-9. - DOI - PMC - PubMed
    1. World Health Organization Coronavirus Disease (COVID-19) Pandemic. [(accessed on 12 December 2023)]. Available online: https://www.who.int/europe/emergencies/situations/covid-19.
    1. World Health Organization Weekly Epidemiological Update on COVID-19. [(accessed on 13 December 2023)]. Available online: https://covid19.who.int/
    1. Horberg M.A., Watson E., Bhatia M., Jefferson C., Certa J.M., Kim S., Fathi L., Althoff K.N., Williams C., Moore R. Post-acute sequelae of SARS-CoV-2 with clinical condition definitions and comparison in a matched cohort. Nat. Commun. 2022;131:5822. doi: 10.1038/s41467-022-33573-6. - DOI - PMC - PubMed
    1. Coronavirus disease (COVID-19): Post-COVID-19 Condition. [(accessed on 18 November 2023)]. Available online: https://www.who.int/news-room/questions-and-answers/item/coronavirus-dis....

LinkOut - more resources